An interventional study of Group 1: Exercise + thermogenic supplement (EX-TS) and Group 2: Exercise + placebo supplement (EX-PL) in Aging, Adults With Overweight and Obesity and Supplementation, sponsored by University of Valencia. Recruiting at 1 site in Spain. Open to participants aged 50 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by University of Valencia · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.
Among the 390 studies in Obesity with a site in Spain, this one is the 224th largest by planned enrollment of the 332 interventional ones that give a count, is one of 43 that started in 2026, is one of 220 with no phase, reaches primary completion later than 40 of the 133 other live ones, and was the 357th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Spain, United States, Germany and 1 more country
Ages 45–65 · Women only
Boehringer Ingelheim · Sites in Spain, United States, Germany and 1 more country
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Spain, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 50 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
390 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 81 · Phase 4 7
First in 2001; this study’s year is marked. 43 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is close to the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 124 across the 332 interventional studies, 128 across the 57 observational. Of the 208 that completed or were terminated, 26 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 390 have an industry lead sponsor. The 10 most frequent:
University of Valencia is the lead sponsor of 357 studies on the registry; 75 are open to participants now.
University of Valencia has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
33 of the studies in Obesity with a site in Spain that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07332273Phase 3Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludLevothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity. | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
Add all 33 to your calendar (.ics) → With an account.
Among the 390 studies in Obesity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Early-onset metabolic disturbances (such as mild hyperglycemia, subclinical dyslipidemia, excess body fat, and reduced functional capacity) represent one of the major public health challenges among middle-aged and older adults. Although body mass index (BMI) remains the primary clinical criterion for classifying excess weight, growing evidence indicates that BMI does not adequately discriminate cardiometabolic risk, particularly in individuals classified as overweight who present elevated body fat levels (Wu et al., 2024).
Several studies have identified altered metabolic phenotypes that do not meet the criteria for obesity, including the so-called "metabolically unhealthy normal weight" (MUNW) or "metabolically unhealthy non-obese" phenotypes. These individuals are characterized by excess body fat, central adiposity, and alterations in glucose and lipid metabolism despite having a non-obese BMI (Stefan, 2020). This profile is associated with increased insulin resistance, low-grade systemic inflammation, and elevated cardiovascular risk, underscoring the need for targeted interventions in "metabolically challenged" individuals. Xiong et al. (2024) demonstrated that metabolic health status independently predicts cardiovascular risk, even when BMI is within non-obese ranges. This evidence supports the rationale of the present project: to intervene in a group of adults without clinical obesity (BMI \< 30 kg/m²) but presenting at least two indicators of mild metabolic dysfunction.
Nutritional supplements with thermogenic properties that promote fat oxidation and satiety-such as phenylcapsaicin, an analog of capsaicin designed to improve bioavailability and reduce pungency, thereby enhancing tolerability in adults-may offer a promising complementary strategy. Recent studies have shown that low doses of phenylcapsaicin were sufficient to increase fat oxidation during exercise, reduce respiratory exchange ratio, and lower maximal heart rate during submaximal testing compared with placebo (Jiménez-Martínez et al., 2023a). Furthermore, additional research reported that phenylcapsaicin improved strength performance, reduced perceived exertion, and attenuated markers of muscle damage following resistance training (Jiménez-Martínez et al., 2023b). These findings suggest that thermogenic and fat-oxidation-enhancing supplementation may act as a safe and effective metabolic modulator, particularly when combined with exercise, positioning it as an innovative strategy for adults presenting mild metabolic risk.
The present study would integrate: (1) a multicomponent functional exercise program designed to improve strength, balance, and aerobic capacity in older adults; (2) a thermogenic and fat-oxidation-enhancing nutritional supplement as a safe metabolic activation strategy; (3) a standardized dietary control protocol to isolate the specific effects of the supplementation; (4) dual-energy X-ray absorptiometry (DXA) for precise body composition assessment; (5) hormonal and lipid biomarkers to evaluate underlying physiological mechanisms; and (6) validated questionnaires addressing quality of life, sleep, and appetite to capture the holistic dimension of this stage of adulthood.
This multidimensional approach would provide an innovative intervention for a growing yet underexplored population: non-obese but metabolically challenged adults at increasing cardiometabolic risk.
References:
The present project is designed as a longitudinal, randomized, controlled, parallel-group, triple-blind clinical trial, with a 12-week active intervention and pre- and post-intervention assessments.
The study will be conducted at a single center (single-center trial) and will include two parallel groups:
Randomization will be performed using balanced block allocation, stratified by sex and baseline body fat percentage, with a 1:1 allocation ratio.
The study will be triple-blind:
The design corresponds to a comparative efficacy trial aimed at evaluating the additional effect of the nutritional supplement compared to placebo, while maintaining identical exercise programming and dietary control in both groups. This approach allows isolation of the specific impact of the supplement on body composition, metabolic function, functional capacity, and perceived health in adults with a metabolically challenged profile but without clinical obesity.
As is standard practice, participants will be informed that their allocation may correspond to either the placebo or experimental group, without disclosure of their actual assignment.
As appropriate in experimental studies, standardized collection of biological samples and psychometric and perceived health data will be conducted at pre- and post-intervention time points to quantify changes in these metrics and analyze them as dependent variables of the applied protocol.
Inclusion Criteria: Individuals will be eligible to participate in the study if they meet all of the following criteria:
Metabolically challenged profile (non-obese): Presence of at least two of the following criteria, in addition to the specified BMI range:
A) Altered body composition (primary criterion): Body fat percentage ≥ 30% in women or ≥ 25% in men, assessed by DXA.
B) Borderline metabolic markers (one or more):
C) Sedentary lifestyle:
Low or very low physical activity level, defined as ≤ 600 MET·min/week according to the IPAQ questionnaire.
Clinical and functional status:
Previous treatment and lifestyle:
Administrative and ethical aspects:
Exclusion Criteria: Individuals presenting any of the following conditions will be excluded from the study:
Clinical obesity or anthropometric extremes:
Relevant or uncontrolled chronic diseases:
Pharmacological treatments interfering with energy metabolism or body weight:
Current use (or use within the previous 3 months) of:
Functional or cognitive limitations:
Substance use:
Other exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive an oral daily dose of the nutritional supplement with thermogenic and appetite-modulating effects in combination with a supervised multicomponent functional exercise program (3 sessions per week, 60 minutes each) for 12 weeks
Dietary Supplement: Group 1: Exercise + thermogenic supplement (EX-TS)
Participants in this group will receive a placebo supplement identical in appearance, color and taste to the active supplement, together with the same multicomponent functional exercise program for 12 weeks
Dietary Supplement: Group 2: Exercise + placebo supplement (EX-PL)
Participants in this group will receive an oral daily dose of the nutritional supplement with thermogenic and appetite-modulating effects in combination with a supervised multicomponent functional program (3 sessions per week, 60 minutes each) for 12 weeks, composed by three exercise blocks: 1) joint mobility and postural control exercises block, 2) functional strength block with three sets of two strength exercises using elastic bands at 70%-85 of 1RM (RPE 6-7 at the beginning and 9 at the end of the set) and, 3) coordination and agility exercises block. Participants will undergo a standardized dietary control plan based on Individualized energy deficit equivalent to 0.7% of body weight per week, adjusted using the Harris-Benedict equation, and macronutrient distribution: protein: 2 g/kg; fat: 0.8 g/kg; remaining energy intake allocated to carbohydrates.
Participants in this group will receive a placebo supplement identical in appearance, color and taste to the active supplement, together with the same multicomponent functional exercise program and dietary control for 12 weeks.
Change in body composition via Dual-Energy X-ray Absorptiometry (DXA)
Whole body and segmental composition will be assessed through Dual-Energy X-ray Absorptiometry (DXA). Parameters analyzed will be: total and regional fat mass and lean mass
Time frame: Pre and post-intervention of 12 weeks
Change in fat distribution via Dual-Energy X-ray Absorptiometry (DXA)
Android/gynoid fat distribution will be analyzed through Dual-Energy X-ray Absorptiometry (DXA).
Time frame: Pre and post-intervention of 12 weeks
Change in hormonal biomarkers (glucagon-like peptide-1;GLP-1)
glucagon-like peptide-1 (GLP-1) will be collected through a blood sample in the morning in a fasted state to assess hormonal state
Time frame: Pre and post-intervention of 12 weeks
Change in hormonal biomarkers (acylated ghrelin)
Acylated ghrelin levels will be collected through a blood sample in the morning in a fasted state to assess hormonal state
Time frame: Pre and post-intervention of 12 weeks
Change in hormonal biomarkers (leptin)
Leptin levels will be collected through a blood sample in the morning in a fasted state to assess hormonal state
Time frame: Pre and post-intervention of 12 weeks
Change in metabolic biomarkers (glucose)
Glucose levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.
Time frame: Pre and post-intervention of 12 weeks
Change in metabolic biomarkers (total cholesterol)
Total cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.
Time frame: Pre and post-intervention of 12 weeks
Change in metabolic biomarkers (HDL cholesterol)
HDL cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.
Time frame: Pre and post-intervention of 12 weeks
Change in metabolic biomarkers (LDL cholesterol)
LDL cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.
Time frame: Pre and post-intervention of 12 weeks
Change in metabolic biomarkers (triglycerides)
Triglycerides levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.
Time frame: Pre and post-intervention of 12 weeks
Change in metabolic biomarkers (creatine)
Creatinine levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.
Time frame: Pre and post-intervention of 12 weeks
Change in metabolic biomarkers (aspartate aminotransferase; ATS)
AST (Aspartate aminotransferase) levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.
Time frame: Pre and post-intervention of 12 weeks
Change in body composition via bioelectrical impedance analysis (BIA)
Whole body fat-free mass will be assessed through bioelectrical impedance analysis (BIA)
Time frame: Pre and post-intervention of 12 weeks
Changes in distance covered/aerobic capacity
Distance covered/aerobic capacity will be assessed through the 6- Minute walking test
Time frame: Pre and post-intervention of 12 weeks
Changes in lower limb strength
Lower limb strength will be assessed through the 30-second Chair Stand Test
Time frame: Pre and post-intervention of 12 weeks
Changes in agility and dynamic balance
Agility and dynamic balance will be assessed through the Timed Up and Go Test
Time frame: Pre and post-intervention of 12 weeks
Changes in handgrip strength
Handgrip strength will be assessed through the Handgrip dynamometry (Jamar Hand Dynamometer).
Time frame: Pre and post-intervention of 12 weeks
Changes in quality of life specific for older adults
Quality of life will be assessed through the World Health Organization Quality of Life-OLD (WHOQOL-OLD) questionnaire
Time frame: Pre and post-intervention of 12 weeks
Changes in general quality of life
Quality of life will be assessed through the Short Form-36 Health Survey (SF-36) questionnaire
Time frame: Pre and post-intervention of 12 weeks
Changes in general health perception
General health perception will be assessed through the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) questionnaire
Time frame: Pre and post-intervention of 12 weeks
Change in sleep quality
Sleep quality will be assessed through Pittsburgh Sleep Quality Index
Time frame: Pre and post-intervention of 12 weeks
Change in perceived insomnia
Perceived insomnia will be assessed through the Insomnia Severity Index
Time frame: Pre and post-intervention of 12 weeks
Change in eating behavior
Eating behavior will be assessed through the Emotional Eater Questionnaire
Time frame: Pre and post-intervention of 12 weeks
Change in appetite behavior
Appetite behavior will be assessed through the Simplified Nutritional Appetite Questionnaire
Time frame: Pre and post-intervention of 12 weeks
Anthropometric changes (waist and hip circumferences)
Waist circumference and hip circumference will be measured
Time frame: Pre and post-intervention of 12 weeks
Anthropometric changes (waist -hip index)
waist -hip index will be measured
Time frame: Pre and post-intervention of 12 weeks
Anthropometric changes (waist to height index)
waist to height index will be measured
Time frame: Pre and post-intervention of 12 weeks
Adherence to supplement and exercise
Adherence to supplement and exercise will be assessed through ad hoc questionnaire
Time frame: Every day for nutritional supplement and each exercise session during the 12 weeks of intervention.
Demographic characteristics (age)
Age will be assessed.
Time frame: Pre and post-intervention of 12 weeks
Demographic characteristics (sex)
Sex will be assessed.
Time frame: Pre and post-intervention of 12 weeks
Demographic characteristics (Body mass index, BMI)
Body mass index (BMI; weight/height2) will be assessed.
Time frame: Pre and post-intervention of 12 weeks
Demographic characteristics (regular medication)
Regular medication will be assessed.
Time frame: Pre and post-intervention of 12 weeks
Started Mar 2026 (actual). Primary completion is estimated for Jul 2026, 4 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 4 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.